MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517044345 A) filed by Spitfire Pharma Llc, Gaithersburg, U.S.A., on May 7, for 'therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist.'
Inventor(s) include Suschak III, John, Joseph; Georges, Bertrand, Victor, Gilbert; Browne, Sarah, K.; Harris, Matthew, Scott; Roberts, M. Scot; and Andrade, Maynara, Lucca.
The application for the patent was published on June 13, under issue no. 24/2025.
According to the abstract released by the Intellectual Property India: "This disclosure relates to the once weekly dosing regimen of a dual GLP-1R and GCGR agonist, formulations, and methods of using the same for treatment of cardiovascular disease/disorder and/or reducing risk factors thereof by inducing reduction of pathogenic serum lipid mediators in a human being, wherein the human may or may not have other comorbidities such as obesity and/or type 2 diabetes. The dual GLP-1R and GCGR agonist includes the peptide product of SEQ ID NO. 1 (pemvidutide)."
The patent application was internationally filed on Nov. 06, 2023, under International application No.PCT/US2023/078850.
Disclaimer: Curated by HT Syndication.
